AAA receives positive CHMP opinion for LysaKare

(Advanced Accelerator Applications) Advanced Accelerator Applications S.A. (AAA), a Novartis company, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization of LysaKare ® 25g/25g (arginine hydrochloride/lysine hydrochloride) solution for reduction of renal (kidney) radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide (Lutathera ® ) in adults.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news